08/02/2026
Public Alert No. 03/2026.
Alert on the circulation of unauthorised and unregistered Risperdal 2 mg tablets brand formulation in Nigeria.
https://bit.ly/4qodiWl
NAFDAC is alerting the public to the circulation of an unauthorised and unregistered Risperdal 2 mg tablet brand formulation in Nigeria, specifically in Kaduna state.
According to Johnson & Johnson, the Marketing Authorisation Holder (MAH), the product batch mentioned in this alert has been confirmed as unauthorised for sale in Nigeria. An internal investigation conducted by the MAH revealed that the batch was intended for the Turkish market but was illegally diverted to Nigeria.
The product was purchased outside the authorised distribution network of Johnson & Johnson in Nigeria.
Risperdal 2 mg tablet is used to treat schizophrenia. It is also used alone or in combination with other medicines to treat mania or mixed episodes (mania and depression) in adults and children above 10 years with bipolar disorder. Risperdal 2 mg Tablet is also used to treat behavioural problems in children aged 5 to 16 years with autism.
Risk Statement
Using unregistered drugs carries serious public health risks, such as potential poisoning, treatment failure, and even death. The safety, quality, and effectiveness of unregistered products cannot be assured, as they have not undergone the necessary evaluations by NAFDAC.
Pharmaceutical products purchased from unauthorised or unregistered sources may be counterfeit, falsified, stolen, recalled, or not approved by local regulatory authorities.
All NAFDAC zonal directors and state coordinators have been instructed to conduct surveillance and remove any unregistered products found within their zones and states.
Healthcare professionals and consumers are advised to report any suspicion of the sale of substandard and falsified medicines or medical devices to the nearest NAFDAC office, call 0800-162-3322, or send an email to sf.alert@nafdac.gov.ng